Patient: Description of condition (onset, main symptoms, hospital visited, etc.): August 10, 2011 Invasive ductal carcinoma, moderately differentiated, with high-grade ductal carcinoma in situ, fibrosis and inflammatory cell reaction around the carcinoma, the mass did not involve the nipple, no carcinoma was seen at the bottom cut edge of surgery, metastatic carcinoma was visible in axillary lymph nodes (1/8) Immunization: ER(++)CrebB-2(++),Ki-67( (20%+),p53(+),E-Cadherin(++),EMA(++),CD34(vascular+)). What should I pay attention to? Zhang Shurong, Cancer Center, Beijing Tongren Hospital: The immunohistochemical test results of tumor tissues only reflect some indicators of tumor characteristics, some reflect the sensitivity of drug treatment, some reflect its proliferation ability, so it is not ideal or unsatisfactory to talk about. It is recommended to test whether Her-2 gene is amplified or overexpressed to decide whether to use targeted therapy. Endocrine therapy is recommended for more than 5 years after the end of chemotherapy.